June 2014

Joseph Flynn, DO, MPH, focuses on the development of novel therapeutics for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in his research at The Ohio State University Comprehensive Cancer Center.

The treatment landscape for patients with non-small cell lung cancer (NSCLC) is poised to undergo dramatic changes, as novel immunotherapies, second-generation targeted therapies, and new maintenance strategies continue to show promise in clinical trials.

As gatekeepers of the cell cycle, the cyclin-dependent kinases are often implicated in the progression of cancer and make prime targets for therapy.

Although oncology researchers seek to describe the significance of clinical trial outcomes with scientific rigor, the terminology used to communicate those findings in the peer-reviewed literature sometimes falls short in conveying the impact that a given therapy may have on patients in a real-world scenario.

Essentially all members of the medical community, including the most "generalist" family practice physicians, are being required to understand and incorporate into their daily practice an ever-increasing quantity of information related to the broad realm of molecular medicine

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.

A recent report on the health consequences of smoking pored through the most recent data and several new findings about smoking and cancer.

When Franco Muggia, MD, was a freshly minted oncologist 50 years ago, his new colleagues warned him not to waste much time learning about a drug like fluorouracil.

Although bacillus Calmette-Guérin (BCG) therapy has significantly improved outcomes for patients with non–muscle invasive bladder cancer since its introduction nearly 40 years ago, there is a pressing need to enhance responses to BCG and to distinguish which patients would respond to treatment early on in the course of therapy.

A regimen of nab-paclitaxel (Abraxane) and gemcitabine is a cost-effective option for the first-line treatment of patients with metastatic pancreatic cancer because it delivers a survival advantage at a price comparable to the cost of an existing combination therapy

The first time Christina T. Giuliano, MD, saw a digital mammogram, she knew the extra clarity and detail would profoundly improve the diagnostic process.

The concept of manipulating the immune system to treat cancer has experienced waxing and waning levels of enthusiasm over decades of clinical investigation.

We are pleased to present the second class of leading oncology specialists whom an esteemed advisory board has chosen to honor with our 2nd Annual Giants of Cancer Careâ„¢ awards.

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.